相似文献
1
Role of RANKL and RANK in bone loss and arthritis.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii32-9. doi: 10.1136/ard.61.suppl_2.ii32.
2
RANKL and RANK as novel therapeutic targets for arthritis.
Curr Opin Rheumatol. 2003 May;15(3):280-7. doi: 10.1097/00002281-200305000-00016.
3
RANK-L and RANK: T cells, bone loss, and mammalian evolution.
Annu Rev Immunol. 2002;20:795-823. doi: 10.1146/annurev.immunol.20.100301.064753. Epub 2001 Oct 4.
4
Bone destruction in arthritis.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii84-6. doi: 10.1136/ard.61.suppl_2.ii84.
5
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Rheumatology (Oxford). 2001 Jun;40(6):623-30. doi: 10.1093/rheumatology/40.6.623.
6
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
JAMA. 2004 Jul 28;292(4):490-5. doi: 10.1001/jama.292.4.490.
7
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Nature. 1999 Nov 18;402(6759):304-9. doi: 10.1038/46303.
8
Osteoprotegerin, RANK, RANKL.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001 Dec;145(2):61-4. doi: 10.5507/bp.2001.013.
9
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Ann Endocrinol (Paris). 2006 Apr;67(2):139-41. doi: 10.1016/s0003-4266(06)72569-0.
10
Osteoclast precursors, RANKL/RANK, and immunology.
Immunol Rev. 2005 Dec;208:19-29. doi: 10.1111/j.0105-2896.2005.00336.x.
引用本文的文献
1
Amelioration of Carrageenan/Kaolin-Induced Arthritis by Benzylideneacetophenone Derivatives in Rats.
Biomol Ther (Seoul). 2025 Jul 1;33(4):680-691. doi: 10.4062/biomolther.2024.242. Epub 2025 Jun 13.
2
The p53-miR17 family-Rankl axis bridges liver-bone communication.
Mol Ther. 2025 Feb 5;33(2):631-648. doi: 10.1016/j.ymthe.2024.12.046. Epub 2024 Dec 31.
3
Effects of Anticancer Therapy on Osteoporosis in Breast Cancer Patients: A Nationwide Study Using Data from the National Health Insurance Service-National Health Information Database.
J Clin Med. 2025 Jan 23;14(3):732. doi: 10.3390/jcm14030732.
4
MicroRNAs in fluorosis pathogenesis: impact on dental, skeletal, and soft tissues.
Arch Toxicol. 2024 Dec;98(12):3913-3932. doi: 10.1007/s00204-024-03853-9. Epub 2024 Sep 13.
5
In Vitro Cell Culture Model for Osteoclast Activation during Estrogen Withdrawal.
Int J Mol Sci. 2024 Jun 1;25(11):6134. doi: 10.3390/ijms25116134.
6
A novel method to efficiently differentiate human osteoclasts from blood-derived monocytes.
Biol Proced Online. 2024 Mar 19;26(1):7. doi: 10.1186/s12575-024-00233-6.
7
SHIP1 deficiency causes inflammation-dependent retardation in skeletal growth.
Life Sci Alliance. 2024 Feb 22;7(5). doi: 10.26508/lsa.202302297. Print 2024 May.
8
The Role of Membrane-Type 1 Matrix Metalloproteinase-Substrate Interactions in Pathogenesis.
Int J Mol Sci. 2023 Jan 22;24(3):2183. doi: 10.3390/ijms24032183.
9
Berberine inhibits RA-FLS cell proliferation and adhesion by regulating RAS/MAPK/FOXO/HIF-1 signal pathway in the treatment of rheumatoid arthritis.
Bone Joint Res. 2023 Feb;12(2):91-102. doi: 10.1302/2046-3758.122.BJR-2022-0269.R1.
10
Exercise Promotes Bone Marrow Microenvironment by Inhibiting Adipsin in Diet-Induced Male Obese Mice.
Nutrients. 2022 Dec 21;15(1):19. doi: 10.3390/nu15010019.
本文引用的文献
1
Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis.
J Exp Med. 2002 Jul 1;196(1):77-85. doi: 10.1084/jem.20020439.
2
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin.
Arthritis Rheum. 2002 Mar;46(3):785-92. doi: 10.1002/art.10097.
3
RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
Histochem Cell Biol. 2002 Mar;117(3):283-92. doi: 10.1007/s00418-001-0376-9. Epub 2002 Jan 26.
4
Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
Bone. 2002 Feb;30(2):340-6. doi: 10.1016/s8756-3282(01)00682-2.
5
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
Arthritis Rheum. 2001 Dec;44(12):2768-76. doi: 10.1002/1529-0131(200112)44:12<2768::aid-art464>3.0.co;2-i.
6
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo.
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13960-5. doi: 10.1073/pnas.251534698.
7
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.
Am J Pathol. 2001 Nov;159(5):1689-99. doi: 10.1016/S0002-9440(10)63016-7.
8
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Rheumatology (Oxford). 2001 Jun;40(6):623-30. doi: 10.1093/rheumatology/40.6.623.
9
IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.
J Clin Invest. 2001 Jun;107(11):1375-85. doi: 10.1172/JCI10530.
10
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Cancer Res. 2001 Jun 1;61(11):4432-6.
Zotero 插件